A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial
Richard S. Finkel(St. Jude Children's Research Hospital), Joanne M. Donovan(Université du Québec à Chicoutimi), James E. MacDougall(BioBridges (United States)), Monique M. Ryan(Royal Children's Hospital), Warren A. Marks(Cook Children's Medical Center), Wolfgang Müller‐Felber(Ludwig-Maximilians-Universität München), M. Tulinius(University of Gothenburg), Jessika Johannsen(Universität Hamburg), Erin Neil Knierbein(Kennedy Krieger Institute), Katherine D. Mathews(University of Iowa), Jessica Nance(Johns Hopkins University), Jeffrey Statland(The University of Texas at San Antonio Health Science Center), Craig M. McDonald(University of California Davis Medical Center), H. Lee Sweeney(University of Florida), Michelle Eagle(Newcastle University), Hugh J. McMillan(Children's Hospital of Eastern Ontario), Cam-Tu Nguyen(Bristol Royal Hospital for Children), Maria Mancini(Catabasis Pharmaceuticals (United States)), Kayal Vijayakumar(University Hospitals Bristol NHS Foundation Trust), Cuixia Tian(Cincinnati Children's Hospital Medical Center), Gary McCullagh(Royal Manchester Children's Hospital), H. Phan(Rare Disease Therapeutics (United States)), Declan O’Rourke(Children's Health Ireland at Crumlin), Kathryn R. Wagner(Kennedy Krieger Institute), Erika Finanger, W. Bryan Burnette(Centre Hospitalier Universitaire Sainte-Justine)
Cited by 32
Related Papers
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
|The Lancet Neurology|2009|2k
Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care
|The Lancet Neurology|2009|1.2k
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
|Neuromuscular Disorders|2019|636
Agalsidase-Beta Therapy for Advanced Fabry Disease
|Annals of Internal Medicine|2007|565
A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy
|Annals of Neurology|2008|466